(GEHC) GE HealthCare Technologies - Ratings and Ratios
Imaging, Ultrasound, Monitoring, Pharmaceuticals
GEHC EPS (Earnings per Share)
GEHC Revenue
Description: GEHC GE HealthCare Technologies
GE HealthCare Technologies Inc. (GEHC) is a leading global provider of healthcare technology solutions, operating through four main segments: Imaging, Advanced Visualization Solutions (AVS), Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). The companys diverse portfolio encompasses a wide range of products and services, including medical imaging equipment, patient monitoring systems, diagnostic agents, and digital solutions.
Key Performance Indicators (KPIs) that can be used to evaluate GEHCs performance include revenue growth, segment-wise profitability, return on equity (RoE), and market share in the healthcare technology industry. With a RoE of 25.87%, GEHC demonstrates a strong ability to generate profits from shareholder equity. The companys market capitalization stands at $34.4 billion, indicating its significant presence in the industry.
GEHCs Imaging and AVS segments are likely to be driven by advancements in medical imaging technologies, such as artificial intelligence (AI) and machine learning (ML). The PCS segments performance will be influenced by the demand for patient monitoring systems and digital solutions. Meanwhile, the PDx segments growth will be driven by the increasing use of diagnostic agents in medical imaging procedures.
To further analyze GEHCs stock performance, one can examine its price-to-earnings (P/E) ratio, which stands at 15.78, and its forward P/E ratio, which is 18.45. These metrics indicate the markets expectations for the companys future earnings growth. Additionally, the stocks technical indicators, such as its relative strength index (RSI) and moving averages, can provide insights into its short-term price movements.
GEHC Stock Overview
| Market Cap in USD | 34,694m |
| Sub-Industry | Health Care Equipment |
| IPO / Inception | 2023-01-04 |
GEHC Stock Ratings
| Growth Rating | -5.64% |
| Fundamental | 67.5% |
| Dividend Rating | 47.8% |
| Return 12m vs S&P 500 | -25.4% |
| Analyst Rating | 4.33 of 5 |
GEHC Dividends
| Dividend Yield 12m | 0.17% |
| Yield on Cost 5y | 0.23% |
| Annual Growth 5y | 15.47% |
| Payout Consistency | 100.0% |
| Payout Ratio | 2.8% |
GEHC Growth Ratios
| Growth Correlation 3m | 17.5% |
| Growth Correlation 12m | -73% |
| Growth Correlation 5y | 22.9% |
| CAGR 5y | 9.52% |
| CAGR/Max DD 3y | 0.25 |
| CAGR/Mean DD 3y | 0.79 |
| Sharpe Ratio 12m | -0.41 |
| Alpha | 0.01 |
| Beta | 0.917 |
| Volatility | 30.18% |
| Current Volume | 2925.4k |
| Average Volume 20d | 3010.7k |
| Stop Loss | 74.3 (-3%) |
| Signal | -0.35 |
Piotroski VR‑10 (Strict, 0-10) 4.5
| Net Income (2.24b TTM) > 0 and > 6% of Revenue (6% = 1.20b TTM) |
| FCFTA 0.03 (>2.0%) and ΔFCFTA -1.64pp (YES ≥ +1.0pp, WARN ≥ +0.5pp) |
| NWC/Revenue 7.81% (prev 2.50%; Δ 5.31pp) (YES ≤20% & Δ≤-1pp; WARN ≤25% & Δ≤0 oder ≤40% & Δ≤-3pp) |
| CFO/TA 0.05 (>3.0%) and CFO 1.65b <= Net Income 2.24b (YES >=105%, WARN >=100%) |
| Net Debt (6.98b) to EBITDA (3.83b) ratio: 1.82 <= 3.0 (WARN <= 3.5) |
| Current Ratio 1.16 (target 1.5–3.0; WARN 1.2–<1.5 or >3.0–5.0; CFO/TA gate active) |
| Outstanding Shares last Quarter (458.0m) change vs 12m ago -0.22% (target <= -2.0% for YES) |
| Gross Margin 41.55% (prev 40.96%; Δ 0.59pp) >=18% & Δ>=+0.5pp (WARN >=15% & Δ>=0) |
| Asset Turnover 59.29% (prev 61.27%; Δ -1.99pp) >=50% & Δ>=+2pp (WARN >=35% & Δ>=0) |
| Interest Coverage Ratio 7.02 (EBITDA TTM 3.83b / Interest Expense TTM 465.0m) >= 6 (WARN >= 3) |
Altman Z'' 1.47
| (A) 0.04 = (Total Current Assets 11.31b - Total Current Liabilities 9.75b) / Total Assets 35.50b |
| (B) 0.12 = Retained Earnings (Balance) 4.29b / Total Assets 35.50b |
| (C) 0.10 = EBIT TTM 3.26b / Avg Total Assets 33.68b |
| (D) 0.13 = Book Value of Equity 3.21b / Total Liabilities 25.55b |
| Total Rating: 1.47 = (6.56 * A) + (3.26 * B) + (6.72 * C) + (1.05 * D) |
ValueRay F-Score (Strict, 0-100) 67.52
| 1. Piotroski 4.50pt = -0.50 |
| 2. FCF Yield 2.95% = 1.48 |
| 3. FCF Margin 6.12% = 1.53 |
| 4. Debt/Equity 1.07 = 1.95 |
| 5. Debt/Ebitda 2.72 = -1.33 |
| 6. ROIC - WACC (= 6.59)% = 8.24 |
| 7. RoE 25.14% = 2.09 |
| 8. Rev. Trend 43.02% = 3.23 |
| 9. EPS Trend 16.77% = 0.84 |
What is the price of GEHC shares?
Over the past week, the price has changed by +0.84%, over one month by +4.73%, over three months by +7.77% and over the past year by -11.55%.
Is GE HealthCare Technologies a good stock to buy?
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of GEHC is around 69.03 USD . This means that GEHC is currently overvalued and has a potential downside of -9.92%.
Is GEHC a buy, sell or hold?
- Strong Buy: 12
- Buy: 4
- Hold: 5
- Sell: 0
- Strong Sell: 0
What are the forecasts/targets for the GEHC price?
| Issuer | Target | Up/Down from current |
|---|---|---|
| Wallstreet Target Price | 88 | 14.8% |
| Analysts Target Price | 88 | 14.8% |
| ValueRay Target Price | 76.2 | -0.5% |
Last update: 2025-09-12 04:37
GEHC Fundamental Data Overview
CCE Cash And Equivalents = 3.74b USD (Cash And Short Term Investments, last quarter)
P/E Trailing = 15.5717
P/E Forward = 16.5017
P/S = 1.7376
P/B = 3.5723
P/EG = 3.4595
Beta = 1.282
Revenue TTM = 19.96b USD
EBIT TTM = 3.26b USD
EBITDA TTM = 3.83b USD
Long Term Debt = 8.27b USD (from longTermDebt, last quarter)
Short Term Debt = 2.13b USD (from shortTermDebt, last quarter)
Debt = 10.40b USD (Calculated: Short Term 2.13b + Long Term 8.27b)
Net Debt = 6.98b USD (from netDebt column, last quarter)
Enterprise Value = 41.36b USD (34.69b + Debt 10.40b - CCE 3.74b)
Interest Coverage Ratio = 7.02 (Ebit TTM 3.26b / Interest Expense TTM 465.0m)
FCF Yield = 2.95% (FCF TTM 1.22b / Enterprise Value 41.36b)
FCF Margin = 6.12% (FCF TTM 1.22b / Revenue TTM 19.96b)
Net Margin = 11.22% (Net Income TTM 2.24b / Revenue TTM 19.96b)
Gross Margin = 41.55% ((Revenue TTM 19.96b - Cost of Revenue TTM 11.67b) / Revenue TTM)
Tobins Q-Ratio = 12.88 (Enterprise Value 41.36b / Book Value Of Equity 3.21b)
Interest Expense / Debt = 1.09% (Interest Expense 113.0m / Debt 10.40b)
Taxrate = 20.57% (531.0m / 2.58b)
NOPAT = 2.59b (EBIT 3.26b * (1 - 20.57%))
Current Ratio = 1.16 (Total Current Assets 11.31b / Total Current Liabilities 9.75b)
Debt / Equity = 1.07 (Debt 10.40b / last Quarter total Stockholder Equity 9.71b)
Debt / EBITDA = 2.72 (Net Debt 6.98b / EBITDA 3.83b)
Debt / FCF = 8.52 (Debt 10.40b / FCF TTM 1.22b)
Total Stockholder Equity = 8.92b (last 4 quarters mean)
RoA = 6.31% (Net Income 2.24b, Total Assets 35.50b )
RoE = 25.14% (Net Income TTM 2.24b / Total Stockholder Equity 8.92b)
RoCE = 18.98% (Ebit 3.26b / (Equity 8.92b + L.T.Debt 8.27b))
RoIC = 14.01% (NOPAT 2.59b / Invested Capital 18.49b)
WACC = 7.42% (E(34.69b)/V(45.10b) * Re(9.39%)) + (D(10.40b)/V(45.10b) * Rd(1.09%) * (1-Tc(0.21)))
Shares Correlation 3-Years: 66.15 | Cagr: 0.07%
Discount Rate = 9.39% (= CAPM, Blume Beta Adj.)
[DCF Debug] Terminal Value 72.87% ; FCFE base≈1.38b ; Y1≈1.33b ; Y5≈1.31b
Fair Price DCF = 40.48 (DCF Value 18.48b / Shares Outstanding 456.6m; 5y FCF grow -4.94% → 3.0% )
EPS Correlation: 16.77 | EPS CAGR: -1.66% | SUE: -0.93 | # QB: 0
Revenue Correlation: 43.02 | Revenue CAGR: 3.32% | SUE: N/A | # QB: None
Additional Sources for GEHC Stock
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle